Results 121 to 130 of about 15,408 (221)

Safety and Immunogenicity of sIPV in Healthy Infants Aged 2 Months Following Sequential Immunization Program Combination with bOPV: A Phase 3, Randomized, Blinded, Parallel Positive-Controlled Clinical Trial. [PDF]

Vaccines (Basel)
Liu Y, Liu X, Zhang L, Chang X, Xiong P, Guan Y, Li Y, Zhang W, Xuan L, Li Y, Ying Z, Xu Q.   +11 more
europepmc   +1 more source

Population immunity to the three serotypes of poliovirus post-interruption of wild poliovirus transmission in Nigeria. [PDF]

J Virus Erad
Baba MM, Kawu AA, Bukar SA, Melton MS, Mala A, Salisu I, Oderinde BS.   +6 more
europepmc   +1 more source

Intramuscular versus intradermal administration of fractional dose inactivated poliovirus vaccine in Mozambique, 2020-2022: an, open-label, non-inferiority, randomised, controlled phase 2 trial. [PDF]

EClinicalMedicine
Omar Viegas E, Fumane E, Pereira K, Amade M, Jani I, Guilche O, Cubai C, Valdez S, Mainou BA, Lopez Cavestany R, Jeyaseelan V, Mach O.   +11 more
europepmc   +1 more source

The Pathogenesis and Virulence of the Major Enterovirus Pathogens Associated with Severe Clinical Manifestations: A Comprehensive Review. [PDF]

Cells
Liu Y, Maisimu M, Ge Z, Xiao S, Wang H.
europepmc   +1 more source

Atomic Force Microscopy of Poliovirus Particles After Inactivation by Chemical Methods and Accelerated Electrons. [PDF]

Viruses
Kraevsky SV, Kanashenko SL, Kolesnichenko AV, Ivin YY, Piniaeva AN, Kovpak AA, Ishmukhametov AA, Budnik SV, Churyukin RS, Shilov OA, Zhdanov DD.   +10 more
europepmc   +1 more source

Estimating proportions of missed children and reasons for non-vaccination following implementation of "reaching the unreached" multiantigen immunization campaign-south Khyber Pakhtunkhwa, Pakistan, July-August 2023. [PDF]

Front Public Health
Ben Hamida A, Alam F, Stewart B, Ahmad S, Sherani EN, Khan H, Adekunle A, Mohamed A, Mbaeyi C, Franka R, Basit A, Safdar R.   +11 more
europepmc   +1 more source

Optimizing preparedness and response for circulating vaccine derived poliovirus (cVDPV) outbreaks in the Eastern Mediterranean Region with a particular focus on cVDPV2. [PDF]

Front Public Health
Haddad N, Jarour N, Shukla H, Tsega A, Akbar I, Mahmoud Qasim Shahrour G, Sekhar Kar S, Al Nsour M, Gunaid M, Khader Y.   +9 more
europepmc   +1 more source

The Double-Edged Sword: How Evolution Can Make or Break a Live-Attenuated Virus Vaccine [PDF]

, 2011

core   +1 more source

Characterization of a Sabin-like type 2/3 recombinant poliovirus with a triple nucleotide deletion in the VP1 region isolated from sewage. [PDF]

Virol J
Lin J, Zhou L, Zhu C, Li J, Zhang W, Zhu S, Wang D, Li X, Zhu H, Yang Q, Ji T, Xiao J, Yang L, Xiao K, Shao K, Zhang Y, Yan D.   +16 more
europepmc   +1 more source

Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial. [PDF]

Lancet Infect Dis
Mercer LD, Seña AC, Colgate ER, Crothers JW, Wright PF, Al-Ibrahim M, Tritama E, Vincent A, Mainou BA, Zhang Y, Konopka-Anstadt J, Bandyopadhyay AS, Fix A, Konz JO, Gast C.   +14 more
europepmc   +1 more source